Italia markets closed

InterCure Ltd. (INCR)

NasdaqGM - NasdaqGM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,6600+0,0100 (+0,38%)
Alla chiusura: 04:00PM EDT
2,5550 -0,10 (-3,95%)
Dopo ore: 06:19PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,6500
Aperto2,6300
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno2,6300 - 2,7000
Intervallo di 52 settimane0,9900 - 2,9200
Volume11.853
Media Volume84.844
Capitalizzazione121,223M
Beta (5 anni mensile)0,24
Rapporto PE (ttm)22,17
EPS (ttm)0,1200
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A33,99
  • GlobeNewswire

    InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY

    Half Year Revenues 2020 to 2023 Half Year Revenues 2020 to 2023 Achieved record revenues of NIS 209 million ($75 million)1 for the first half of 2023 Annualized revenue run rate of NIS 417 million ($149 million) Adjusted EBITDA2 of NIS 30 million ($11 million) Generated NIS 35 million ($13 million) cash from operations in the second quarter Strong balance sheet with over NIS 116 million ($42 million) cash and financial assets3 of NIS 71 million ($25 million) NEW YORK and HERZLIYA, Israel, Aug. 3

  • GlobeNewswire

    InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE

    NEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company"), announced today that its board of directors (“Board”) has approved the voluntarily delisting of the Company’s common shares (“Shares”) from the Toronto Stock Exchange (the “TSX”) (the “Delisting”). The Company has decided to delist from the TSX after concluding that maintaining the listing does not offer substantial ben

  • GlobeNewswire

    InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

    NEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company"), reports today that, further to the Company’s press release issued on February 1, 2023, where the Company had reported the termination of the merger agreement (the “Agreement”) with Cann Pharmaceutical Ltd. ("Better") due to fundamental disagreements between the parties thereto and that the closing conditions contained i